REQUEST A DEMO
Total
USD $0.00
Search more companies

PT Meiji Indonesian Pharmaceutical Industries (Indonesia)

Main Activities: Pharmaceutical Preparation Manufacturing
Full name: PT Meiji Indonesian Pharmaceutical Industries Profile Updated: November 25, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2024 Available in: English Download a sample report

Meiji Indonesian Pharmaceutical Industries is primarily engaged in pharmaceutical preparations, nec activity. Its headquarters is located in Dki Jakarta. The company was founded in 1974. Meiji Indonesian Pharmaceutical Industries is a subsidiary of Meiji Seika Pharma Co., Ltd., a prominent Japanese pharmaceutical company. The company was established to cater to the growing demand for pharmaceutical products in Indonesia and the Southeast Asian region. It focuses on the production and distribution of a wide range of pharmaceutical products, including antibiotics, over-the-counter medications, and prescription drugs. The company operates several manufacturing facilities in Indonesia, ensuring high-quality production standards and compliance with international regulations. Meiji Indonesian Pharmaceutical Industries has a strong local presence with multiple branches across major cities in Indonesia, enhancing its distribution network and accessibility to healthcare providers and consumers. Globally, Meiji Seika Pharma Co., Ltd. has a significant presence, with operations in various countries across Asia, Europe, and the Americas. This global footprint allows Meiji Indonesian Pharmaceutical Industries to leverage international expertise and resources to enhance its product offerings and technological capabilities. The company is committed to innovation and research, continuously investing in the development of new pharmaceutical products and therapies. It collaborates with various research institutions and industry partners to advance healthcare solutions and improve patient outcomes. Meiji Indonesian Pharmaceutical Industries is a member of several pharmaceutical and healthcare associations, actively participating in industry initiatives and contributing to the development of the pharmaceutical sector in Indonesia. The company's mission is to provide high-quality, affordable healthcare products to improve the well-being of communities in Indonesia and beyond.

Headquarters
Jl. Prof. Dr. Soepomo No. 40, Tebet
South Jakarta; Jakarta; Postal Code: 12870

Contact Details: Purchase the PT Meiji Indonesian Pharmaceutical Industries report to view the information.

Website: http://www.meiji.co.id

Basic Information
Total Employees:
Purchase the PT Meiji Indonesian Pharmaceutical Industries report to view the information.
Registered Capital:
Purchase the PT Meiji Indonesian Pharmaceutical Industries report to view the information.
Financial Auditors:
Purchase the PT Meiji Indonesian Pharmaceutical Industries report to view the information.
Incorporation Date:
May 13, 1974
Key Executives
Purchase this report to view the information.
President Director
Purchase this report to view the information.
President Commissioner
Purchase this report to view the information.
President Commissioner
Purchase this report to view the information.
President Commissioner
Purchase this report to view the information.
President Commissioner
Ownership Details
Purchase this report to view the information.
Purchase this report to view the information.
Purchase this report to view the information.
Purchase this report to view the information.
Purchase this report to view the information.
Company Performance
Financial values in the chart are available after PT Meiji Indonesian Pharmaceutical Industries report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency IDR. Absolute financial data is included in the purchased report.
Net sales revenue
10.66%
Total operating revenue
10.66%
Total assets
13.43%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?